should be less pronounced than those seen in a normal postovulatory endometrium. Nonetheless, the endometrium does undergo cyclical changes resembling normal ones, and these changes are probably sufficiently different from the normal to prevent nidation should "escape" ovulation and fertilization occur.
The traditional mainstays of cancer treatment have been surgery and radiotherapy and more recently chemotherapy. Immunotherapy offers hope, but is at present largely experimental. Until recently these disciplines were often found in isolation from each other and some patients were given treatments which were inappropriate for their disease. An important introduction into the investigation and management of cancer has been the concept of oncology as a specialty. Surgery Cancer surgery has reached a level of technical achievement beyond which it is unlikely that important advances will be made. Its established role in palliation is, of course, vital, and a newer role in the pathological staging of several tumour types has developed. The use of irradiation as an adjunct in the surgical management of tumours of borderline operability or inoperable tumours at several sites is being intensively investigated. Chemotherapy as an adjunct to surgery in tumours with a high propensity for metastatic spread may be of value in some casesfor example, in osteogenic sarcoma and carcinoma of the breast.
Radiotherapy
During the past two decades rapid technological advances have occurred in radiotherapy; kilovoltage machines have been superseded by megavoltage apparatus generating penetrating beams of high energy x-rays at high dose rates, and the precision, ease, and adapatability of treatment planning methods have been
The Royal Marsden Hospital, Sutton, Surrey T. J. MCELWAIN, M.B., M.R.C.P., Consultant Physician M. J. PECKHAM, M.D., F.F.R., Professor of Radiotherapy improved by the introduction of simulators, mould room facilities, and computers. These developments, together with improved tumour localization techniques, have facilitated the treatment of most deep-seated tumours with a high degree of accuracy.
Successful radiotherapy must be based on precise tumour localization. Isotope scanning has achieved some success, ultrasonic scanning now shows considerable promise for obtaining details of tumour localization and volume for planning treatment.
Surgical staging procedures have been particularly useful in Hodgkin's disease, demonstrating occult splenic involvement in about 40% of patients with apparently localized nodal disease. There may be room for further improvement in achievingprecise distrubiton of radiation dose within these accurately identified structures. For example, the possibility of employing proton beams together with x-ray beams to treat inaccessible sites such as the pancreas and the advantages of using beams of negative pi-mesons to achieve the same end is currently under discussion.
When optimal dose distribution has rarely posed a problemfor example, in skin cancer-the cure rate with irradiation has been excellent. The same is true for glottic cancer. Significant advances have, however, also been made in Hodgkin's disease,' based on two factors: tumour localization, and the ability to give tumoricidal doses to deeply placed nodes-for example, in the mediastinum and retroperitoneal areas. In bladder cancer radical radiotherapy was impracticable before the introduction of supervoltage irradiation, which can cure about 20% of advanced lesions,2 a proportion which is likely to be considerably improved by the planned sequential use of irradiation and surgery. In Radiotherapy and Surgery The failure of radiation therapy consistently to control bulky, locally extensive carcinomas and the failure of surgical excision (due either to spillage of tumour cells at operation or to occult local exte-ision remaining after the procedure) argue in favour of a combined approach. The objective ofthe combined approach may be to eradicate metastases, to reduce tumour bulk, or to render non-viable the superficial cells of the tumour and thus prevent local recurrence: often the aim will be to realize all three objectives. On the whole, workers have preferred preoperative rather than postoperative irradiation, though there are no conclusive data in man to support this approach. Moreover, few controlled studies have been carried out on the use of the combined approach in several sites. Nevertheless, Roswit et al.11 reported that the number of lymph nodes infiltrated by tumour was significantly reduced in those patients with carcinoma of the rectum and rectosigmoid colon receiving 2,000 to 3,000 rads preoperatively. In this controlled study the life At present tumours are eradicated very seldom owing to many factors-among which are the innate resistance of some of the tumour cells to the drugs; failure of the drugs to gain access to the tumour; our inability to know how long to continue treatment; and the dose-limiting side effects of the drugs. Unfortunately, high doses of drugs are more toxic than low doses to normal rapidly dividing cell systems such as the gut mucosa and bone marrow. Nevertheless, since these tissues have a greater capacity for rapid repair than most tumours, intermittent administration of high doses of drugs can result in a stepwise loss of tumour cells at the cost of transient reversible toxicity to the host. But the bone marrow, gut, skin, liver, kidney, and gonads may all be damaged by cytotoxic drugs and this has to be remembered when treatment schedules are being designed; this has resulted in very large doses of drugs being given to patients over short periods with rest periods between treatments, rather than small doses of drugs being given continuously as was the practice in the past.
The latter type of treatment has been called "relapse orientated" since, though it may produce remissions and prolong life, there is little hope of tumour eradication. High-dose intermittent chemotherapy is "cure oriented" since it is aimed at total tumour eradication-though this seldom occurs except in special cases, such as chorioncarcinoma. Since drug combinations are usually used on a high-dose intermittent basis, this method of treatment should result in a much increased tumour cell kill--and in fact this is the case. Significant responses are seen, for example, in tumours of the breast, bronchus (oat-cell), skin, ovary, testis, and in many of the embryonal tumours of childhood. This suggests that if such chemotherapy was applied earlier in these diseases, subclinical foci of cancer might be permanently eradicated. The term adjuvant chemotherapy is usually applied to this addition of drug treatment to primary treatment with either radiotherapy or surgery. There are two ways of doing this.
INITIAL ADJUVANT THERAPY
Chemotherapy may be given first to relieve symptoms or to make the surgery or radiotherapy technically simpler. Examples are the use of nitrogen mustard to relieve rapidly superior vena caval obstruction by carcinoma of the bronchus before radiotherapy, and the use of methotrexate or bleomycin to reduce the volume of head and neck tumours before surgery or radiotherapy, which makes the subsequent treatment easier and reduces damage to normal structures. SUBSEQUENT 
ADJUVANT THERAPY
The second sort of adjuvant chemotherapy is where the drugs are given after primary treatment with surgery and radiotherapy to prevent the appearance of metastases and thus to increase the proportion of patients surviving disease free. This type of chemotherapy has found its widest application in the treatment of children's tumours, many of which, though apparently localized at the time of presentation, give rise to distant metastases later.
In theory, the time to eradicate the metastases is when they are composed of very few cells and are clinically undetectable rather than when they are clinically obvious and composed of many tumour cells-and this has proved true in practice. The use of adjuvant chemotherapy in Wilm's tumour, Ewing's tumour, and rhabdomyosarcoma has significantly increased the proportion of long survivors and the principle is currently being tested in the management of testicular teratoma, cerebellar medulloblastoma, and breast cancer-where adjuvant combination chemotherapy has now been shown to increase survival in selected patients known to be at high risk for recurrence of tumour.
Though adjuvant chemotherapy has proved successful, it is a crude approach to the problem, since there is no way of knowing which patients will develop metastases and which will not. Hence it is necessary to overtreat some patients who will not develop metastases for the sake of those who will. One may hope that developments in subclinical tumour detectionthrough, for example, index substances-may help to solve this problem.
Immunotherapy
The demonstration of specific tumour-associated antigens and of host response to them has provided a rational basis for immunotherapy, but this is still an experimental area at present and the casual administration to patients with cancer of killed tumour cells or their products, or adjuvant substances such as B.C.G. has little to commend it and much against it. The technique is potentially dangerous, unlikely to be effective, and serves mainly to confuse the issues in an already much confused area. Nevertheless, some success has been achieved, mainly in acute leukaemia, and there is every justification for properly conducted controlled clinical studies in which not only clinical but proper immunological measurements are made. The subject has been well reviewed by Currie.12 Conclusions Progress in controlling solid tumours has been slow and until recently results have been disappointing. We are now hopefully on the brink of new advances, as scientists and clinicians increasingly band together to tackle the many problems that cancer presents.
In particular, the recognition that cancer is frequently a generalized disease which should be treated early with methods aimed at eradicating subclinical foci of disease should improve the prognosis for some patients in the future.
